Rapamycin as an adjunctive therapy for NLRC4 associated macrophage activation syndrome

Frontiers in Immunology

Volumn 9, Issue SEP, 2018, Pages

  Barsalou, Julie ^a   Blincoe, Annaliesse ^a   Fernandez, Isabel ^a,b   Dal Soglio, Dorothée ^a,b   Marchitto, Lorie ^a,b   Selleri, Silvia ^a   Haddad, Elie ^a,b   Benyoucef, Aissa ^a   Touzot, Fabien ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

IL 18; IL 1 ; Inflammasome; Macrophage activation syndrome; mTOR; NLRC4; Rapamycin

Indexed keywords

ADENOSINE TRIPHOSPHATE; C REACTIVE PROTEIN; FERRITIN; HLA DR ANTIGEN; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPOLYSACCHARIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MEPREDNISONE; NIGERICIN; NLRC4 INFLAMMASOME; PERFORIN; RAPAMYCIN; UNCLASSIFIED DRUG; URATE; CALCIUM BINDING PROTEIN; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; IL1B PROTEIN, HUMAN; NLRC4 PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; AIR CONDITIONING; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOINFLAMMATORY DISEASE; BLOODY DIARRHEA; BODY WEIGHT GAIN; BODY WEIGHT LOSS; BONE MARROW BIOPSY; CASE REPORT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE RELEASE; ENTEROCOLITIS; ENZYME ACTIVATION; EOSINOPHIL; ERYTHROPHAGOCYTOSIS; FEVER; GAIN OF FUNCTION MUTATION; HEMOPHAGOCYTIC SYNDROME; HEPATOSPLENOMEGALY; HUMAN; HYPERFERRITINEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN VITRO STUDY; INFANT; INFLAMMATORY CELL; INOTROPISM; INTESTINE MUCOSA; LYMPHOCYTOPENIA; MACROPHAGE; MACROPHAGE ACTIVATION SYNDROME; MALE; METABOLIC ACIDOSIS; MONOCYTE; MONOCYTE DERIVED MACROPHAGE; MTOR SIGNALING; NATURAL KILLER CELL; PROTEIN EXPRESSION; RECTUM BIOPSY; T LYMPHOCYTE; THROMBOCYTOPENIA; TROUGH CONCENTRATION; VASOPLEGIA; FEMALE; GENETICS; IMMUNOLOGY; PATHOLOGY;

CALCIUM-BINDING PROTEINS; CARD SIGNALING ADAPTOR PROTEINS; CASPASE 1; FEMALE; GAIN OF FUNCTION MUTATION; HUMANS; INTERLEUKIN-18; INTERLEUKIN-1BETA; MACROPHAGE ACTIVATION SYNDROME; SIROLIMUS;

EID: 85054895813     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.02162     Document Type: Article

References (15)

1. Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. (2014) 46:1135-9. doi: 10.1038/ng.3066
2. Gabrion A, Hmitou I, Moshous D, Neven B, Lefèvre-Utile A, Diana J-S, et al. Mammalian target of rapamycin inhibition counterbalances the inflammatory status of immune cells in patients with chronic granulomatous disease. J Allergy Clin Immunol. (2017) 139:1641-9.e6. doi: 10.1016/j.jaci.2016.08.033
3. Ko JH, Yoon S-O, Lee HJ, Oh JY. Rapamycin regulates macrophage activation by inhibiting NLRP3 inflammasome-p38 MAPK-NFκB pathways in autophagy- and p62-dependent manners. Oncotarget (2017) 8:40817-31. doi: 10.18632/oncotarget.17256
4. Munk RB, Sugiyama K, Ghosh P, Sasaki CY, Rezanka L, Banerjee K, et al. Antigen-independent IFN-γ production by human naïve CD4 T cells activated by IL-12 plus IL-18. PLoS ONE (2011) 6:e18553. doi: 10.1371/journal.pone.0018553
5. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA, et al. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem. (2011) 286:9587-97. doi: 10.1074/jbc.M110.202911
6. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood (2010) 116:e74-80. doi: 10.1182/blood-2010-02- 258558
7. Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, et al. Life-threatening NLRC4- associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. (2017) 139:1698-701. doi: 10.1016/j.jaci.2016.10.022
8. Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell (2016) 165:792-800. doi: 10.1016/j.cell.2016.03.046
9. Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. (2014) 46:1140-6. doi: 10.1038/ng.3089
10. Zhang L, Chen S, Ruan J, Wu J, Tong AB, Yin Q, et al. Cryo-EM structure of the activated NAIP2-NLRC4 inflammasome reveals nucleated polymerization. Science (2015) 350:404-9. doi: 10.1126/science.aac5789
11. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. (2016) 12:259-68. doi: 10.1038/nrrheum.2015.179
12. Weiss ES, Girard-Guyonvarc'h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin- 18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood (2018) 131:1442-55. doi: 10.1182/blood-2017-12-820852
13. Rauch I, Deets KA, Ji DX, von Moltke J, Tenthorey JL, Lee AY, et al. NAIP-NLRC4 inflammasomes coordinate intestinal epithelial cell expulsion with eicosanoid and IL-18 release via activation of caspase-1 and -8. Immunity (2017) 46:649-59. doi: 10.1016/j.immuni.2017.03.016
14. Moghaddas F, Zeng P, Zhang Y, Schützle H, Brenner S, Hofmann SR, et al. Autoinflammatory mutation in NLRC4 reveals a leucine-rich repeat (LRR)-LRR oligomerization interface. J Allergy Clin Immunol. (2018) doi: 10.1016/j.jaci.2018.04.033. [Epub ahead of print].
15. Marsh RA, Haddad E. How i treat primary haemophagocytic lymphohistiocytosis. Br J Haematol. (2018) 182:185-99. doi: 10.1111/bjh.15274